Mechanism of action of SNS-032, a novel cyclin dependent kinase inhibitor, in chronic lymphocytic leukemia: Comparison with flavopiridol.

被引：3

作者：

Chen, Rong ^{[1
]}

Wierda, William G. ^{[1
]}

Benaissa, Sherri ^{[1
]}

Hoch, Ute ^{[2
]}

Hawtin, Rachael E. ^{[2
]}

Fox, Judith A. ^{[2
]}

Keating, Michael J. ^{[1
]}

Gandhi, Varsha ^{[1
]}

Plunkett, William ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Sunesis Pharmaceut, San Francisco, CA USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.3112.3112

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3112

引用

页码：915A / 915A

页数：1

共 50 条

[31] The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo
Xie, Gui'e
Tang, Hongping
Wu, Shaoqing
Chen, Jingsong
Liu, Jiangwen
Liao, Can
INTERNATIONAL JOURNAL OF ONCOLOGY, 2014, 45 (02) : 804 - 812
[32] Dinaciclib (SCH 727965) Is a Novel Cyclin-Dependent Kinase (CDK) Inhibitor That Exhibits Activity In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia (CLL)
Flynn, Joseph M. M.
Andritsos, Leslie A.
Jones, Jeffrey A.
Johnson, Amy J.
Maddocks, Kami
Wiley, Elizabeth
Small, Karen
Im, Eun Kyung
Grever, Michael R.
Bannerji, Rajat
Byrd, John C.
Zhou, Honghong
BLOOD, 2013, 122 (21)
[33] The cyclin dependent kinase inhibitor SCH 727965 demonstrates dramatic pre-clinical activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia
Johnson, Amy
Smith, Lisa
Raymond, Chelsey
Lucas, David
Flynn, Joseph
AbuTarif, Malaz
Statkevich, Paul
Bannerji, Rajat
Byrd, John
CANCER RESEARCH, 2009, 69
[34] Mechanism of action of the multikinase inhibitor TG02 in chronic lymphocytic leukemia
Chen, Rong
Tsai, Jennifer
Chen, Yuling
Burrows, Francis
Wierda, William
Plunkett, William
CANCER RESEARCH, 2012, 72
[35] Preclinical testing of a novel Axl-kinase inhibitor in Chronic Lymphocytic Leukemia
Goebel, M.
Moellmann, M.
Goergens, A.
Huettmann, A.
Duehrsen, U.
Giebel, B.
Unger, A.
Choidas, A.
Duerig, J.
ONKOLOGIE, 2013, 36 : 172 - 172
[36] Preclinical Testing of a Novel Axl-Kinase Inhibitor in Chronic Lymphocytic Leukemia
Goebel, Maria
Moellmann, Michael
Goergens, Andre
Duehrsen, Ulrich
Huettmann, Andreas
Giebel, Bernd
Unger, Anke
Choidas, Axel
Duerig, Jan
BLOOD, 2012, 120 (21)
[37] Preclinical Testing Of a Novel Axl-Kinase Inhibitor In Chronic Lymphocytic Leukemia
Goebel, Maria
Moellmann, Michael
Goergens, Andre
Duehrsen, Ulrich
Goethert, Joachim Rudolf
Giebel, Bernd
Schultz-Fademrecht, Carsten
Unger, Anke
Klebl, Bert
Choidas, Axel
Duerig, Jan
BLOOD, 2013, 122 (21)
[38] The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
Johnson, A. J.
Yeh, Y-Y
Smith, L. L.
Wagner, A. J.
Hessler, J.
Gupta, S.
Flynn, J.
Jones, J.
Zhang, X.
Bannerji, R.
Grever, M. R.
Byrd, J. C.
LEUKEMIA, 2012, 26 (12) : 2554 - 2557
[39] The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells
A J Johnson
Y-Y Yeh
L L Smith
A J Wagner
J Hessler
S Gupta
J Flynn
J Jones
X Zhang
R Bannerji
M R Grever
J C Byrd
Leukemia, 2012, 26 : 2554 - 2557
[40] The Cyclin Dependent Kinase Inhibitor SCH 727965 Demonstrates Promising Pre-Clinical and Early Clinical Activity in Chronic Lymphocytic Leukemia
Flynn, Joseph M.
Johnson, Amy J.
Andritsos, Leslie
Blum, Kristie A.
Jones, Jeffrey A.
Wiley, Elizabeth A.
Hu, Weihong
Hessler, Joshua
Smith, Lisa L.
Lucas, David M.
Small, Karen
Statkevich, Paul
Grever, Michael R.
Bannerji, Rajat
Byrd, John C.
BLOOD, 2009, 114 (22) : 365 - 365

← 1 2 3 4 5 →